|
Fig. 8 Normal neo-vascularization and activation of FGF signaling after blocking Cxcr4 function. (A-D) fli1-EGFP (green) and cmlc2a-mCherry (magenta) signal in the control (A,C) and CXCR4-antagonist-treated (B,D) heart at 7 dpa (A,B) and 14 dpa (C,D). Arrowheads point to neo-vascularization in the regenerating area, visualized by the fli1-EGFP signal. (E) Quantitation of neo-vascularization. The fli-EGFP positive area compared with the regenerating area was measured and by ImageJ software. A section at the center of the injury site of each heart was examined (n=3). (F-I) FGF signaling status, visualized by phospho ERK1/2 (pERK1/2) immunoreactivity (F,G) and expression of mkp3/dusp6 (H,I) at 14 dpa in control (F,H) and CXCR4 antagonist-treated (G,I) hearts. The arrowheads point to the pERK1/2 (F,G) and mkp3/dusp6 (H,I) signals. The dotted lines indicate the amputation planes. Scale bars: 50 μm.